国药一致 (000028.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

10.7x

EV/EBITDA

4.6x

Market Cap

CNY 11.99B

MomentumView details →

1D Return

+0.62%

YTD Return

−17.79%

RSI (14)

49.9

ValuationView details →

P/E (Fwd)

10.7x

EV/EBITDA

4.6x

Market Cap

CNY 11.99B

RSI (14)

49.9

MomentumView details →

1D Return

+0.62%

YTD Return

−17.79%

ProfitabilityView details →

Gross Margin

10.59%

Net Margin

1.50%

EBITDA Margin

4.03%

ROE (TTM)

5.80%

ROA (TTM)

2.23%

Asset Turnover

1.49x

GrowthView details →

Revenue YoY

−0.86%

EPS YoY

+89.42%

FCF YoY

−81.22%

Revenue CAGR 3Y

−0.01%

EPS CAGR 3Y

−8.58%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.52

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.50

Avg Surprise (4Q)

0.00%

Rev Surprise

−8.75%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

1.56x

Quick Ratio

1.23x

Div Yield

3.36%

Div Rate

CNY 0.68

Div Growth 1Y

+85.14%

Financials snapshotView financials →

Revenue (TTM)

72.95B

Net Income (TTM)

1.10B

Op. CF (TTM)

520.53M

Next earningsOct 22, 2026 →

Latest newsMore news →

Sinopharm Group Co., Ltd. announced its 2026 half-year results with net profit attributable to shareholders of 606 million yuan, down 8.97% year-on-year.18d ago

Similar companies

北方国际000065.SZ 爱施德002416.SZ 江苏国泰002091.SZ 百洋医药301015.SZ ST易购002024.SZ 厦门港务000905.SZ Find similar companies →

Latest newsMore news →

Sinopharm Group Co., Ltd. announced its 2026 half-year results with net profit attributable to shareholders of 606 million yuan, down 8.97% year-on-year.18d ago